HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[A phase II study of vindesine for pretreated non-small cell lung cancer].

Abstract
A phase II evaluation of vindesine (VDS) was performed in 16 patients with non-small cell lung cancer (ten patients with adenocarcinoma, six patients with squamous cell carcinoma, and one patient with large cell carcinoma). All except one of the patients had had prior chemotherapy. VDS at a dose of 3 mg/m2 was given intravenously every week for more than three weeks. Among 16 evaluable patients, two patients with pretreated adenocarcinoma of the lung showed partial response. The response rate for VDS was 12.5%. Toxic effects included leukopenia (94%), anemia (44%), thrombopenia (13%), alopecia (38%), peripheral neurotoxicity (38%), liver injury (19%), constipation (13%), anorexia (13%), nausea (13%), stomatitis (6%) and fever (6%).
AuthorsE Shimizu, Y Nakamura, K Yamasaki, K Kimura, I Inoue, S Nakahira, K Kawahito, K Tani, S Sone, T Yamashita
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 14 Issue 8 Pg. 2532-6 (Aug 1987) ISSN: 0385-0684 [Print] Japan
PMID3039921 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Vindesine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Small Cell (drug therapy)
  • Drug Evaluation
  • Female
  • Humans
  • Lung Neoplasms (drug therapy)
  • Male
  • Middle Aged
  • Vindesine (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: